Treatment-resistant depression and the bipolar spectrum: Recognition and management

Primary Psychiatry

Volumn 13, Issue 11, 2006, Pages 59-67

  Thase, Michael E ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; DOPAMINE RECEPTOR STIMULATING AGENT; DULOXETINE; ESCITALOPRAM; GABAPENTIN; LAMOTRIGINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; THYROID HORMONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VALPROMIDE; VENLAFAXINE;

BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DRUG CHOICE; DRUG HYPERSENSITIVITY; DYSLIPIDEMIA; ELECTROCONVULSIVE THERAPY; HUMAN; HYPERTENSION; MAJOR DEPRESSION; METABOLIC DISORDER; MONOTHERAPY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RASH; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN DISEASE; SLEEP DEPRIVATION; THERAPY RESISTANCE; WEIGHT GAIN;

EID: 33845230892     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (90)

1. Thase ME. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr. 2004;9(11):808-816, 818-821.
2. Saggese JM, Lieberman DZ, Goodwin FK. The role of recurrence and cyclicity in differentiating mood disorder diagnoses. Primary Psychiatry. 2006;13(11):43-48.
3. Rush AJ, Thase ME, Dube S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry. 2003;53(8):743-753.
4. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.
5. Thase ME. Comparing the efficacy of the newer antidepressants. In: Gilaberte I, ed. Nuevas Perspectivas en la Fepresión. Madrid, Spain: Aula Médica Endiciones; 2004:253-286.
6. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 2005;66(8):974-981.
7. Thase ME. Managing depressive and anxiety disorders with escitalopram. Expert Opin Pharmacother. 2006;7(4):429-440.
8. Barbui C, Guaiana G, Hotopf M. Amitriptyline for inpatients and SSRIs for outpatients with depression? Systematic review and meta-regression analysis. Pharmacopsychiatry. 2004;37(3):93-97.
9. Anderson IM. Meta-analytical studies on new antidepressants. Br Med Bull. 2001;57:161-178.
10. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000;157(suppl 4):1-45.
11. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231-1242.
12. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-1252.
13. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
14. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006;163(7):1161-1172.
15. McGrath PJ, Stewart JW, Fava M, et al. A comparison of tranylcypromine to the combination of venlafaxine-XR plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. In press.
16. Nierenberg AA, Fava M, Trivedi MH, et al. A Comparison of Lithium and T3 Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report. Am J Psychiatry. 2006;163(9):1519-1530.
17. Perris C. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Acta Psychiatr Scand Suppl. 1966;194:1-188.
18. Cluss PA, Marcus SC, Kelleher KJ, Thase ME, Arvay LA, Kupfer DJ. Diagnostic certainty of a voluntary bipolar disorder case registry. J Affect Disord. 1999;52(1-3):93-99.
19. Coryell W. Bipolar II disorder: a progress report. J Affect Disord. 1996;41(3):159-162.
20. Dunner DL, Tay LK. Diagnostic reliability of the history of hypomania in bipolar II patients and patients with major depression. Compr Psychiatry. 1993;34(5):303-307.
21. Ghaemi NS. Hippocrates and prozac: the controversy about antidepressants in bipolar disorder. Primary Psychiatry. 2006;13(11):51-58.
22. Thase ME. Bipolar depression: issues in diagnosis and treatment. Harv Rev Psychiatry. 2005;13(5):257-271.
23. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry, 2003;64(2):161-174.
24. Akiskal HS, Walker P, Puzantian VR, King D, Rosenthal TL, Dranon M. Bipolar outcome in the course of depressive illness. Phenomenologic, familial, and pharmacologic predictors. J Affect Disord. 1983;5(2):115-128.
25. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(suppl 4):1-50.
26. Kupfer DJ, Pickar D, Himmelhoch JM, Detre TP. Are there two types of unipolar depression? Arch Gen Psychiatry. 1975;32(7):866-871.
27. Goodwin FK, Jamison KR. Manic-Depressive Illness. London, England: Oxford University Press; 1990.
28. Weissman MM, Bland RC, Camino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA. 1996;276(4):293-299.
29. Angst J. Bipolar disorder - a seriously underestimated health burden. Eur Arch Psychiatry Clin Neurosci. 2004;254(2):59-60.
30. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003;73(1-2):123-131.
31. Akiskal HS, Hantouche EG, Allilaire JF, et al. Validating antidepressant-associated hypomania (bipolar III): a systematic comparison with spontaneous hypomania (bipolar II). J Affect Disord. 2003;73(1-2):65-74.
32. Diagnostic and Statistical Manual of Mental Disorders. 4th ed text rev. Washington, DC: American Psychiatric Association; 2000.
33. Akiskal HS, Benazzi F. The DSM-IV and ICD-10 categories of recurrent [major] depressive and bipolar II disorders: evidence that they lie on a dimensional spectrum. J Affect Disord. 2006;92(1):45-54.
34. Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry. 2000;61(10):804-808.
35. Chun BJ, Dunner DL. A review of antidepressant-induced hypomania in major depression: suggestions for DSM-V. Bipolar Disord. 2004;6(1):32-42.
36. Stoll AL, Mayer PV, Kolbrener M, et al. Antidepressant-associated mania: a controlled comparison with spontaneous mania. Am J Psychiatry. 1994;151(11):1642-1645.
37. Strober M, Carlson G. Predictors of bipolar illness in adolescents with major depression: a follow-up investigation. Adolesc Psychiatry. 1982;10:299-319.
38. Akiskal HS. Searching for behavioral indicators of bipolar II in patients presenting with major depressive episodes: the "red sign," the "rule of three" and other biographic signs of temperamental extravagance, activation and hypomania. J Affect Disord. 2005;84(2-31:279-290.
39. Akiskal HS, Maser JD, Zeller PJ, et al. Switching from 'unipolar' to bipolar II. An 11-year prospective study of clinical and temperamental predictors in 559 patients. Arch Gen Psychiatry. 1995;52(2):114-123.
40. Braunig P, Kruger S, Shugar G. Prevalence and clinical significance of catatonic symptoms in mania. Compr Psychiatry. 1998;39(1):35-46.
41. Akiskal HS, Benazzi F. Atypical depression: a variant of bipolar II or a bridge between unipolar and bipolar II? J Affect Disord. 2005;84(2-3):209-217.
42. Benazzi F. Symptoms of depression as possible markers of bipolar II disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(3):471-477.
43. Perugi G, Akiskal HS, Lattanzi L, et al. The high prevalence of "soft" bipolar (II) features in atypical depression. Compr Psychiatry. 1998;39(2):63-71.
44. Benazzi F. Depression with DSM-IV atypical features: a marker for bipolar II disorder. Eur Arch Psychiatry Clin Neurosci. 2000;250(1):53-55.
45. Benazzi F, Koukopoulos A, Akiskal HS. Toward a validation of a new definition of agitated depression as a bipolar mixed state (mixed depression). Eur Psychiatry. 2004;19(2):85-90.
46. Maj M, Pirozzi R, Magliano L, Fiorillo A, Bartoli L. Agitated "unipolar" major depression: prevalence, phenomenology, and outcome. J Clin Psychiatry. 2006;67(5):712-719.
47. Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disord. 2005;85(3):245-258.
48. Thase ME, Sachs GS. Bipolar depression: pharmacotherapy and related therapeutic strategies. Biol Psychiatry. 2000;48(6):558-572.
49. Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies. J Clin Psychopharmacol. 1999;19(5):427-434.
50. Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry. 2003;64(suppl 5):44-52.
51. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003;290(11):1467-1473.
52. Fagiolini A, Buysse DJ, Frank E, Houck PR, Luther JF, Kupfer DJ. Tolerability of combined treatment with lithium and paroxetine in patients with bipolar disorder and depression. J Clin Psychopharmacol. 2001;21(5):474-478.
53. Marangell LB, Martinez JM, Ketter TA, et al. Lamotrigine treatment of bipolar disorder: data from the first 500 patients in STEP-BD. Bipolar Disord. 2004;6(2):139-143.
54. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999;60(2):79-88.
55. Muzina DJ, Calabrese JR. Pharmacological profile and clinical utility of lamotrigine in bipolar disorders. In: Akiskal HS, Tohen M, eds. Bipolar Psychopharmacotherapy: Caring for the Patient. Hoboken, NJ; John Wiley & Sons; 2006:44-62.
56. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 2000;20(6):607-614.
57. Nierenberg AA, Ostacher MJ, Calabrese JR, K, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006;163(2):210-216.
58. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry. 2000;61(11):841-850.
59. Bowden CL, Asnis GM, Ginsberg LD, Bentley B, Leadbetter R, White R. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf. 2004;27(3):173-184.
60. Baker RW, Tohen M, Fawcett J, et al. Acute dysphoric mania: treatment response to olanzapine versus placebo. J Clin Psychopharmacol. 2003;23(2):132-137.
61. Vieta E, Calabrese JR, Hennen J, et al. Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data. J Clin Psychiatry. 2004;65(10):1420-1428.
62. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079-1088.
63. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158(1):131-134.
64. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351-1360.
65. Thase ME, MacFadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the bolder II study). J Clin Psychopharmacol. In press.
66. Newcomer JW, Haupt DW, Flavin KS, et al. Atypical antipsychotic treatment effects on metabolic outcome. Schizophr Bull. 2005;31(2):566.
67. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs. 2004;64(7):701-723.
68. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163(4):611-622.
69. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry. 1994;55(9):391-393.
70. Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006;163(2):232-239.
71. Thase ME, Shelton RC, Khan A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol. 2006;26(3):250-258.
72. Vieta E, Martinez-Aran A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry. 2002;63(6):508-512.
73. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998;59(10):502-508.
74. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995;12(3):185-219.
75. Himmelhoch JM, Fuchs CZ, Symons BJ. A double-blind study of tranylcypromine treatment of major anergic depression. J Nerv Ment Dis. 1982;170(10):628-634.
76. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry. 1991;148(7):910-916.
77. Thase ME, Mallinger AG, McKnight D, Himmelhoch JM. Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry. 1992;149(2):195-198.
78. Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL. Possible monoamine oxidase inhibitor-serotonin reuptake inhibitor interaction: fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol. 1993;13(5):312-320.
79. Thase ME. Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression. J Clin Psychiatry. 2006;67(4):671-672.
80. Bauer M, London ED, Rasgon N, et al. Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression. Mol Psychiatry. 2005;10(5):456-469.
81. Carton PJ, Merlock MG, Suppes T. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord. 2004;6(5):416-420.
82. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161(3):564-566.
83. Cassano P, Lattanzi L, Soldani F, et al. Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety. 2004;20(3):131-138.
84. Sohn CH, Lam RW. Treatment of seasonal affective disorder: unipolar versus bipolar differences. Curr Psychiatry Rep. 2004;6(6):478-485.
85. Altshuler LL, Frye MA, Gitlin MJ. Acceleration and augmentation strategies for treating bipolar depression. Biol Psychiatry. 2003;53(8):691-700.
86. Lam DH, Watkins ER, Hayward P, et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry. 2003;60(2):145-152.
87. Frank E, Kupfer DJ, Thase ME, et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry. 2005;62(9):996-1004.
88. Miklowitz DJ, George EL, Richards JA, Simoneau TL, Suddath RL. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry. 2003;60(9):904-912.
89. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: 3 randomized controlled trial. JAMA. 2001;285(10):1299-1307.
90. Nahas Z, Marangell LB, Husain MM, et al. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry. 2005;66(9):1097-1104.